<DOC>
	<DOCNO>NCT00311051</DOCNO>
	<brief_summary>The purpose study examine wether combination Ramatroban/Montelukast effective Montelukast alone patient mild moderate atopic asthma ( GINA I II ) sensitive house dust mite . The test perform specific inhalative provocation .</brief_summary>
	<brief_title>Ramatroban/Montelukast Versus Montelukast/Placebo Early Allergic Reaction Asthma Sensitive House Dust Mite</brief_title>
	<detailed_description>In early allergic response asthma , allergens connect IgE mast cell basophile granulocyte . For 3 main pathway activation : Besides quick liberation Histamine induction cytokine liberation mediator arachidonate metabolism . In addition Histamine especially Prostaglandin PGD2 , Leukotriene LTC4 also Thromboxane A2 classic symptom early allergic reaction responsible . All mediator potent bronchoconstrictive activity . Prostaglandin D2 Thromboxane A2 work Thromboxane receptor . LTC4 links Cys-LT-receptors . According in-vitro-model early allergic reaction human precision-cut lung slice passive specific sensitization grass-pollen , show early allergic response suppress partly give Antihistamines , Leukotriene receptor antagonist Thromboxane receptor antagonist . It go consent clinical finding , drug alone insufficient activity asthma . In described human in-vitro-model combination Thromboxane receptor antagonist Leukotriene receptor antagonist ( Montelukast ) block early response asthma completely . These finding rationale study far clinical data effect combination Leukotriene receptor antagonist ( Montelukast ) Thromboxane receptor antagonist . The drug Montelukast Leukotriene receptor antagonist know treatment mild moderate asthma Germany . According GINA-Guidelines Montelukast give addition steroid Î²-mimetics asthma severity grade II III . The drug Ramatroban Thromboxane A2 receptor antagonist Japan allow treatment allergic rhinitis . It also anti-asthmatic effect block bronchoconstriction , hyperresponsiveness airway infiltration inflammation cell . Furthermore , positive effect allergic rhinitis block permeability capillary , block nasal hyperresponsiveness infiltration mucosa eosinophil . During study Ramatroban prove save drug indication allergic rhinitis also allergic asthma . In contrast sufficient effectiveness indication allergic rhinitis say insufficient effectiveness indication asthma . About combination Ramatroban Montelukast exist clinical data study hand examines effect Ramatroban/Montelukast versus Montelukast/Placebo early allergic reaction patient mild moderate atopic asthma ( GINA I II ) sensitive house dust mite specific inhalative provocation .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<mesh_term>Ramatroban</mesh_term>
	<criteria>Atopic ( house dust mite ) asthma Severity GINA one two No reaction specific bronchial provocation test Other kind clinical relevant atopic reaction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Allergens</keyword>
	<keyword>house dust mite</keyword>
	<keyword>Ramatroban</keyword>
	<keyword>Montelukast</keyword>
	<keyword>Bronchial Provocation Tests</keyword>
</DOC>